Turin Study Maps Why Multiple Myeloma Escapes Anti-CD38 Immunotherapy
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.
Summary
Multiple myeloma is a blood cancer that frequently relapses after standard therapies. Anti-CD38 drugs like daratumumab have transformed treatment, but many patients eventually stop responding. This completed Italian clinical study enrolled 40 relapsed myeloma patients to systematically collect bone marrow and blood samples before, during, and after anti-CD38 therapy. By analyzing plasma cells, B cells, and immune cells at multiple timepoints, researchers aimed to identify the genetic mutations and cellular changes that drive resistance. Understanding these mechanisms could help oncologists predict who will respond, detect resistance earlier, and design combination therapies that overcome it. The study represents a carefully structured biobanking effort, with samples stored at the University of Turin for ongoing molecular analyses.
Detailed Summary
Multiple myeloma remains one of the most challenging blood cancers to treat because of its near-universal tendency to relapse. While proteasome inhibitors and immunomodulatory drugs have extended survival, patients who progress on these agents urgently need effective salvage options. Anti-CD38 monoclonal antibodies such as daratumumab have emerged as a cornerstone of relapsed therapy, yet durable remissions are far from guaranteed, and acquired resistance is a growing clinical problem.
This completed observational study at the University of Turin enrolled 40 multiple myeloma patients who had relapsed or become refractory to proteasome inhibitors or immunomodulatory drugs and were subsequently assigned to anti-CD38-based salvage regimens. The design was longitudinal and biobank-driven, collecting bone marrow aspirates, peripheral blood, plasma, and buccal swabs at tightly defined timepoints: baseline, every three months, at best response, and at relapse or refractory status.
The study's core innovation lies in its multi-compartment sampling strategy. CD138-positive plasma cells and CD138/CD19-positive B cells were immunomagnetically enriched for downstream genomic and phenotypic analyses. Peripheral blood mononuclear cells were isolated in parallel to characterize the immune microenvironment. Germline DNA from buccal swabs served as patient-matched controls, enabling somatic variant detection.
Although final results from the completed trial are not yet publicly reported in this abstract, the framework is designed to yield insights into which genomic alterations, surface antigen changes, and immune cell dynamics predict or mediate anti-CD38 resistance. Such findings could ultimately inform biomarker-driven patient selection and novel therapeutic combinations.
The study is limited to 40 patients at a single institution, which constrains statistical power and generalizability. Importantly, this summary is based solely on the trial registration abstract; full results, analyses, and conclusions have not been reviewed here.
Key Findings
- 40 relapsed myeloma patients receiving anti-CD38 salvage therapy were enrolled and longitudinally sampled.
- Bone marrow and blood collected at baseline, during response, and at relapse to map resistance evolution.
- Plasma cells, B cells, and immune cells isolated separately to identify cellular drivers of treatment failure.
- Germline DNA controls enable precise detection of acquired somatic mutations linked to resistance.
- Multi-timepoint design allows tracking of how anti-CD38 resistance develops dynamically over treatment course.
Methodology
Prospective observational study enrolling 40 relapsed/refractory multiple myeloma patients at a single Italian center. Serial bone marrow and peripheral blood sampling at predefined clinical timepoints enabled longitudinal genomic and immunophenotypic profiling. Samples were biobanked at the University of Turin for centralized multi-platform analyses.
Study Limitations
This summary is based on the trial registration abstract only; full results, data, and conclusions were not available for review. The small sample size of 40 patients at a single institution limits statistical power and generalizability to broader myeloma populations. No efficacy or survival outcomes are reported in the available abstract.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.